NCT06299852 2024-03-08
Stereotactic Radiation Therapy for HE2-positive Oligometastatic Breast Cancer
N.N. Petrov National Medical Research Center of Oncology
Phase NA Unknown
Clinical Trials
12 trialsNCT04197687 2023-12-18
TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery
Academic and Community Cancer Research United
Phase 2 Unknown
NCT04591431 2023-10-03
ROME
Fondazione per la Medicina Personalizzata
Phase 2 Unknown
NCT05755048 2023-09-01
FS-1502 Versus T-DM1 for HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Phase 3 Unknown
NCT04924699 2023-03-17
A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer
Shanghai Miracogen Inc.
Phase 2/3 Unknown
NCT05754502 2023-03-03
Observational Study of Effectiveness and Safety of Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Residual Invasive Disease Following Neoadjuvant Chemotherapy and Anti-HER2 Target Therapy
Consorzio Oncotech
Unknown
NCT05560308 2022-10-03
Phase II Clinical Study of T-DM1 and Pyrotinib Maleate in Patients With HER2-positive Metastatic Breast Cancer Who Had Progressed on TKI Therapy
Tianjin Medical University Cancer Institute and Hospital
Phase NA Unknown
NCT05429684 2022-06-23
Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer
First Affiliated Hospital Xi'an Jiaotong University
Phase 3 Unknown
NCT04769050 2022-04-20
Dynamic Observational Study With PET of 68Ga-HER2-affibody in Anti-HER2 Treatment
Fudan University
Unknown
NCT04158947 2020-05-12
HER2BAT
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Unknown
NCT03418558 2018-10-31
RESCUE
Fondazione del Piemonte per l'Oncologia
Phase 2 Unknown
NCT03225937 2018-10-30
HERACLES
Fondazione del Piemonte per l'Oncologia
Phase 2 Unknown